When: Close above $138 on volume >7M shares

Then: Invalidates bearish distribution thesis; bullish confirmation

When: Yeztugo Q3 >$1.1B and golden cross confirmed

Then: Upgrade to Buy with target $152–155

HOLD

• The death cross is not confirmed - 50 SMA still below 200 SMA - the gap has narrowed and 50 is curling up but the cross hasn't flipped, making medium-term trend mathematically unresolved
• Bollinger upper band at $136.39 has repeatedly rejected price - August 5-7 distribution bar on 11.4M shares wicking to $137.80 and closing $130.86, today's intraday high at $136.85 again rejected at the band
• Buying at the ceiling of a range ($135.77) after a 12 percent recovery rally from June lows risks becoming exit liquidity for next distribution wave
• Fundamentals are strong (Yeztugo at $1B with 70% persistence, 13.75 forward P/E, 0.33 beta, 2.47% yield) but macro headwinds make the risk-reward unfavorable near-term
• $11.2B IPR&D charge is non-cash but crushed book value from $23.5B to $11.8B and raised net debt from $14.5B to $23.1B - institutional managers will not look past the headline GAAP loss
• Polymarket pricing 86% probability of zero Fed cuts in 2026 creates a risk-off environment; CPI print this week adds uncertainty
• Multiple headwinds: Trodelvy-Keytruda Phase III scrapped, AIDS Healthcare Foundation publicly attacking HIV pricing (reputational overhang), IBD flagging stock as in a downtrend despite Q2 beat
• The tiered entry plan (1% at $131, second tranche at $129.50) with stop at $120.69 and 2-3% total sizing is precisely calibrated - starting now at $135.77 breaks the math on blended cost basis ($132.50) and stop loss distance (9%)
• Risk to HOLD is bounded and theoretical (missing move to $150 while earning 0% on cash); risk of buying now is realized and immediate (5-10% drawdown probability from multiple headwinds)

→ vs aggressive: The death cross IS a lagging signal by construction, but the conservative analyst reframes it as a structural confirmation filter - the aggressive view conflates 'lagging' with 'unimportant' when the math shows the medium-term trend is unresolved until the cross flips

→ vs aggressive: Walking the upper Bollinger band is only bullish in a confirmed uptrend - the aggressive analyst ignores that the upper band has been used as resistance for weeks with repeated failures at $136.39, which is a ceiling pattern, not a bull flag

→ vs aggressive: Good fundamentals do not override price action - IBD is calling the post-earnings action a downtrend in real time; when the market disagrees with your fundamental thesis, you wait for price to agree, not double down

→ vs aggressive: Non-cash IPR&D charges still hit book value ($23.5B to $11.8B) and leverage ($14.5B to $23.1B net debt), and no institutional manager will read past the GAAP headline loss headline in a risk-off macro environment

→ vs aggressive: The 1 to 1.5 percent starter compromise sounds reasonable but creates operational drift - either the trader adds the second tranche (getting the blended entry) or doesn't (stuck with a position the plan wasn't sized to operate standalone), and breaking entry discipline invalidates stop loss and position sizing math

BUY (modified tiered entry)

• Starter position: 0.5-1% portfolio at $135-136, framed as confirmation position rather than breakout buy
• Second tranche reserved for either 50 SMA retest or confirmed golden cross, whichever prints first
• Blended cost target: $132-133 if both tranches fill
• Stop loss adjusted to $124-125 (from $120.69) reflecting blended entry; ~9-10% below blended cost
• Total position size: 2-3% portfolio weight
• Forward P/E on entry: 13.5x range
• Time horizon: 6-9 months for fundamental re-rating thesis
• Yeztugo persistence >70% drives bull case; BofA and Zacks already characterized as beat-and-raise
• 11.4M share distribution Aug 5-7 at 137.80 wick/130.86 close shows supply at upper band not yet absorbed
• 50 SMA at 129.52 rising toward 200 SMA at 131.01; gap compressed to $1.49
• Stock trading 11% off June low ($120.69), indicating institutional smart money has discounted write-off noise
• CPI print this week could trigger pullback opportunity for second tranche; be ready to deploy
• ATR: 4.10; beta 0.33 makes GILD relatively defensive in risk-off environment

→ vs aggressive: Death cross at 50 SMA 129.52 approaching 200 SMA 131.01 is not a 'ghost' - institutional trend screens will flag as 'below crossover' until cross prints, blocking multiple expansion despite leading oscillators flipping bullish

→ vs aggressive: Upper Bollinger band ($136.40) 'strength signal' argument fails because every poke above has failed; 11.4M share distribution Aug 5-7 proves supply exists at that level that hasn't been absorbed

→ vs aggressive: Asymmetric upside scenario incomplete - entry at $135.77 with compressed multiple and failed cross could mean retest of 200 SMA ($131) then June low ($120.69), a 7-11% drawdown not priced in

→ vs conservative: Death cross as primary filter is circular logic - waiting for lagging signal to confirm price action the lagging signal is designed to confirm; over-weighting lagging tool relative to leading indicators already flipped

→ vs conservative: 'No institutional manager will read past write-off headline' is empirically wrong - BofA explicitly cited >70% Yeztugo persistence as bull case; stock 15 points above where it would trade if optics truly blocked flows

→ vs conservative: 'Wait for $129.50-$131 pullback' zone is a moving target - 50 SMA rising to 132-133 by time of retest means waiting months while missing fundamental catalysts; opportunity cost unpriced